問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Taichung Veterans General Hospital

Division of Thoracic Medicine

更新時間：2023-11-06

羅永鴻Luo, Yung-Hung
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

151Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

羅永鴻

List

220Cases

2026-04-01 - 2029-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-10-01 - 2035-01-20

Phase III

Not yet recruiting
Beamion LUNG-3: A randomized, controlled, multicenter study evaluating zongertinib as adjuvant monotherapy versus standard of care in patients with early-stage, resectable non-small cell lung cancer (stage II–IIIB) harboring activating HER2 mutations in the tyrosine kinase domain.

  • Condition/Disease

    Early, resectable non-small cell lung cancer (stage II to IIIB) with HER2 mutations involving activating alterations in the tyrosine kinase domain

  • Test Drug

    Injection Film-coated tablet Injection Injection Injection

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2025-12-31

Phase II

Completed
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

  • Condition/Disease

    Small Cell Lung Carcinoma、 Neuroendocrine Neoplasms 、Extra-pulmonary Neuroendocrine Carcinoma

  • Test Drug

    N/A

Participate Sites
3Sites

Terminated3Sites

2025-10-01 - 2028-12-31

Phase II/III

Active
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    EGFR-mutated Non-small Cell Lung Cancer

  • Test Drug

    powder

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2034-06-01

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2017-09-01 - 2027-03-09

Phase III

Completed
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

  • Condition/Disease

    Melanoma, metastatic

  • Test Drug

    NIVOLUMAB SINJ 100MG(1VLX10); IPILIMUMAB SINJ200MG(1VLX4)

Participate Sites
4Sites

Terminated4Sites

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

江起陸
Taipei Veterans General Hospital

Division of Thoracic Medicine

2020-04-01 - 2025-11-26

Phase III

Completed
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Condition/Disease

    Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL OPDIVO (nivolumab) Injection 10mg/mL YERVOY (ipilimumab) Injection 5mg/mL YERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2015-11-01 - 2025-08-29

Phase III

Completed
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Nivolumab

Participate Sites
5Sites

Terminated5Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-01-01 - 2024-11-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-08-01 - 2026-12-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≥ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    NON-SMALL CELL LUNG CANCER (NSCLC)

  • Test Drug

    RO5424802(Alctinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

1 13 14 15 16 17 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB